If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
There is no information on the use of tirzepatide in patients with cancer because patients with a history of an active or untreated malignancy or in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years were excluded from tirzepatide clinical trials.
Date of Last Review: February 05, 2021